Gastrointestinal treatment-related adverse events of combined immune checkpoint inhibitors: a meta-analysis.

Combined immune checkpoint inhibitors can cause gastrointestinal adverse events. We performed a meta-analysis of pooled colonic, hepatic and pancreatic treatment-related adverse events of combined ICI. 53 trials reporting treatment-related adverse events in 6581 patients. All grade diarrhea was the most common adverse event seen in 25.4% patients, followed by all grade hepatitis in nearly 13% patients and pancreatitis in nearly 7.5% patients. Our study provides pooled data of treatment-related adverse events from different combination immune checkpoint inhibitors use in solid tumors and demonstrates a high incidence of all grades and ≥3 grade gastrointestinal adverse events. Further studies are required to characterize these adverse events and assess their overall impact on treatment course and outcomes.